Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilarin Central and Eastern Europe.
Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilar in Central and Eastern Europe.
The proposed trastuzumab biosimilar will be seeking indications to treat human epidermal receptor 2 (HER2)-positive breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The potential biosimilar is currently in phase 3 clinical development and will be marketed as Hervelous.
“I am pleased to partner with Prestige BioPharma to further expand our biosimilar portfolio in the region… We have managed to secure a leading position in biosimilars in the region, with a robust portfolio of leading molecules for the treatment of oncology, rheumatoid arthritis, and anemia and the expected addition of [a] trastuzumab biosimilar will be a great addition to our biosimilar assets,” commented Hacho Hatchikian, executive vice president of Alvogen.
The agreement includes the exclusive rights for Alvogen to commercialize the proposed biosimilar in all of its Central and Eastern European markets. Although the exact terms of the arrangement have not been publicly disclosed, Prestige BioPharma will assume the responsibility of development and product registration with the European Medicines Agency (EMA), as well as the commercial supply of the biosimilar out of its manufacturing facilities in Osong, South Korea.
The companies plan to file with the EMA and the FDA for regulatory approval in 2019.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).